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Abstract——More than 95% of genes in the human
genome are alternatively spliced to form multiple
transcripts, often encoding proteins with differing or
opposing function. The control of alternative splicing is
now being elucidated, and with this comes the oppor-
tunity to develop modulators of alternative splicing
that can control cellular function. A number of ap-
proaches have been taken to develop compounds that
can experimentally, and sometimes clinically, affect
splicing control, resulting in potential novel therapeu-
tics. Here we develop the concepts that targeting
alternative splicing can result in relatively specific
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pathway inhibitors/activators that result in dampening
down of physiologic or pathologic processes, from
changes in muscle physiology to altering angiogenesis
or pain. The targets and pharmacology of some of the
current inhibitors/activators of alternative splicing are
demonstrated and future directions discussed.
I. Introduction
The human genome generates up to a million differ-
ent proteins from a genetic code that contains just over
20,000 distinct genes. There is therefore a substantial
increase in diversity between the genetic code and the
proteome that functions to control how cells behave,
interact, and form complex tissues and organs. One of
the principal mechanisms of this diversity is the gen-
eration of multiple mRNA splice forms from a single
genetic unit by the process of alternative splicing. Al-
though this process has been known about for nearly
50 years, the mechanisms underlying its control in
health and disease are only now becoming understood
sufficiently well that intervention in the process can be
considered as a potential therapeutic approach. Over
the last few years a number of pharmacological strat-
egies have been developed to target alternative splicing
in disease states, and some of these have now reached
the clinical trial stage, with surprising, sometimes
promisingly efficacious, results. However, the genera-
tion of new drugs that target splicing raises a number of
challenges that are relatively restricted to this type of
agent. These challenges, both real and perceived, need
to be addressed when developing such agents. The poten-
tial for novel, potent, efficacious therapeutics in this field
is clearly enormous, but the barriers to successful drug
development need to be understood, negotiated, overcome,
and sometimes eliminated for this potential to be real-
ized. A comprehension of the principles of the alternative
splicing process, its regulation, and the concepts that
underlie coordinated alternative splicing is required so
that common initial concerns about these pharmacolog-
ical approaches can be relieved. In this review we intend
to layout the principles behind the development of
approaches to regulate alternative splicing in health and
disease.
II. Methods
Searches of PubMed, Web of Science, and clinicaltrials.
gov were used to identify papers, citations, and clinical
trials, respectively, which addressed the field of splicing
and development of novel therapeutics. Background in-
formation was gleaned from recent reviews, textbooks,
and integrated from the authors’ own knowledge of the
systems. Search terms inPubMedused to identify primary
sources included: Alternative Splicing AND therapeutics
(716 hits) and Alternative Splicing AND clinical trial
(86 hits). From these searches, areas of disease and
mechanisms of action were further explored, includ-
ing searches on cancer, apoptosis, angiogenesis, pain,
muscular dystrophy, and then drilled down in terms
of mechanisms and target molecules. This was fol-
lowed up by searches using clinicaltrials.gov, Google,
and Web of Science to identify additional information
about the targets.
III. Alternative Splicing
Alternative splicing is the process of combinatorial re-
arrangementof exons, parts of exons, and/orparts of introns
into mature RNA to result in a multitude of transcripts.
It has only recently been shown to be extensive across
the human genome, with more than 94% of genes being
alternatively spliced (Pan et al., 2008; Wang et al., 2008).
This makes alternative splicing one of the main drivers of
proteome diversity and therefore a major regulatory level
for cell functions. Interestingly, although conservation at
the DNA sequence level is quite high in vertebrates,
alternative splicing (AS) is less conserved in the evolution-
ary tree, with a degree of similarity between human and
mouse of only ;30% (Barbosa-Morais et al., 2012).
The spliceosome, a macromolecular complex formed of
many proteins as well as small nuclear ribonucleopro-
teins, is the machinery that performs the removal of re-
gions of theRNA – introns - and joining of regions destined
to form mature mRNA – exons (Will and Lührmann,
2011). It does this by assembling at splice sites, regions at
the junction between exons and introns, which are fairly
well conserved. Through complex binding of the proteins
and RNA in the spliceosome with the target RNA se-
quence, the introns are spliced out with the occurrence of
two trans-esterification reactions. This involves the up-
stream and downstream intronic splice sites – so-called 59
and 39 splice sites – and a conserved sequence on the
intron called the branch point. A region rich in pyrimidine
nucleotides (C and T) helps the spliceosome assemble
through binding of various splice factors and is also one of
the main features of a basic splicing reaction (Fig. 1).
There are several modes of alternative splicing: an
exonmaybe included or excluded in the final transcript—
known as a cassette exon; two exonsmay be alternatively
included or skipped—mutually exclusive exons; alterna-
tively, 59 or 39 splice sites may be used or a whole intron
ABBREVIATIONS: AS, alternative splicing; CLK, CDC2-like kinase; DMM, Duchenne’s muscular dystrophy; DYRK, dual-specificity
tyrosine-regulated kinases; ESE, exonic splicing enhancer; ESS, exonic splicing silencer; hnRNP, heterogeneous nuclear ribonucleoproteins;
ISE, intronic splicing enhancer; ISS, intronic splicing silencer; NGF, nerve growth factor; PIM, proviral insertion site in Moloney murine
leukemia virus; PRP, pre-mRNA processing factor; SF, splice factor; SMA, spinal muscle atrophy; SRPK, SR-rich splicing factor protein
kinases; TF, tissue factor; VEGF, vascular endothelial growth factor.
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may be retained. These rearrangements may occur
either in the coding or noncoding region of the mRNA.
When occurring in the 59 or 39 untranslated regions it
does not affect the protein sequence but may regulate
its expression.
Analogous to transcription, alternative splicing is
regulated by both cis- and trans-acting elements. Both
introns and exons have regions that may affect the
inclusion/exclusion of certain exons—cis-acting ele-
ments found on the RNA. Depending on whether they
are inhibitory or stimulatory for certain splicing events,
they are termed exonic splicing silencer or enhancer
(ESS or ESE) and intronic splicing silencer or enhancer
(ISS or ISE) sequences (Fig. 1). They often work through
binding of trans-acting elements, often proteins called
splice factors (SF). Several RNA-binding proteins are
classified as SFs. Two of the major classes are SR
proteins (containing serine arginine-rich motifs) and
heterogeneous nuclear ribonucleoproteins (hnRNPs).
Classically, SR proteins were thought as activators
and hnRNPs as silencers of AS; however, recent evi-
dence shows that depending on the context each can act
both ways (Fu and Ares, 2014). An increasing number of
RNA binding proteins are also characterized as SFs
outside of these major classes, many of them regulating
cell- and tissue-specific splicing events [e.g., epithelial
splicing regulatory proteins (ESRP) 1 and 2, CELF
(cytidine-uridine-guanidine binding protein and Elav-
like family), RbFox1 and 2, Muscleblind like (Mbnl)]
(Kalsotra et al., 2008;Warzecha et al., 2009; Singh et al.,
2014; Pedrotti et al., 2015).
IV. Targets within Alternative Splicing
The regulation of alternative splicing can be targeted
therapeutically by devising agents that interfere either
with the RNA
• As it is transcribed and screened by the splicing
machinery;
• By modifying and preventing RNA binding
proteins from recognizing their RNA targets or
their actions on the splicing machinery; or
• By regulating the controlling agents that allow
the RNA binding proteins to carry out their
splicing actions.
A. Nucleotide Binding Agents
To complete splicing at a specific point in the RNA
sequence, the splicing factors need to be able to
recognize specific sequences. There have been a number
of attempts to define consensus sequences for various
splicing proteins, and themost widely studied now have
semispecific sequences that can be searched for to
investigate splice sites. However, RNA splicing se-
quences are not as fixed as, for instance, DNA tran-
scription factor consensus sequences (De Conti et al.,
2013), and the ability of splicing factors to bind to their
consensus sequences is clearly highly dependent on
local secondary and tertiary RNA structure (Rosonina
andBlencowe, 2004), bindingwith other proteins (Bradley
et al., 2015), and many other factors and processes that
take place within the cells. Despite this, it has been
possible to generate short sequences of RNA that can
specifically interfere with alternative splicing. There
have been two main approaches:
a. Design complementary nucleotide sequences to
specific splice regions such that splicing is skipped.
These dominant negative splicing inhibitors have
taken the form of either RNA or modified RNAs that
can interfere with specific targeted sequences. For
example, in spinal muscular atrophy (SMA) (Osman
et al., 2014; Rigo et al., 2014) apoptosis, DNA repair
response (MDM4 function) (Dewaele et al., 2016; Li
et al., 2016), and in other conditions.
b. RNA sequences can be used that are targets for
specific splicing factors that can then be used to
position the splicing factors at a specific splice point
or mop up splicing factors so that they cannot act on
their targets. One example is targeted oligonucleo-
tide enhancers of splicing (Smith et al., 2014) and
another is to use alternative intronic splicing si-
lencers [ISS (Singh et al., 2015)], which can then be
used to stimulate or repress splicing to a specific exon,
respectively.
Fig. 1. Control of splicing. Cis acting elements, such as exon splicing enhancer sequences (ESE), exon splicing silencers (ESS), intron splicing silencers
(ISS), and intron splicing enhancers (ISE) are bound by trans-acting elements (splicing factors, SF) that facilitate or repress splicing. At the 39 end of
the intron, a consensus AG splice site is preceded by a polypyrimidine (pY) tract and a branch point that requires a consensus splice site (YNYURAY,
R = purine, U = uridine). The complex of factors bound to the 59 splice site (gray region) interacts with the complex bound to the 39 site (gray region) to
induce and regulate splicing.
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B. RNA Binding Agents
A growing number of RNA binding proteins, such as
the classic SR proteins and the proteins that form the
basis of the splicing factor machinery, have been
identified as taking part in splicing—alternative or
constitutive—and it has been found that modulation
of these can result in changes in expression of splice
isoforms. For example, small molecule inhibitors of
SRSF1 have been developed (Bakkour et al., 2007),
whereas the SF3B family of proteins have been targeted
by a number of compounds such as spliceostatin (Kaida
et al., 2007) and pladienolide B (Kotake et al., 2007).
A recent approach has been to use a generic screen,
whereby alternative splicing constructs are used to
screen chemical libraries that can identify compounds
that alter alternative splicing in a nonbiased manner—
i.e., not depending on themechanism of action (Naryshkin
et al., 2014; Palacino et al., 2015). This has resulted in a
number of compounds where the mechanisms of action
are unknown or only postulated [e.g., sudemycins, postu-
lated to be through SF3b (Fan et al., 2011), or aryl-thiazol-
piperidines, where no mechanism of action is known (Fan
et al., 2011) and may not even be splicing modulators but
differential posttranscriptional regulators].
C. Splicing Factor Regulatory Proteins
Splicing occurs, and alternative splicing is regulated,
by the interaction of a host of proteins that form the
spliceosome but do not directly bind to RNA and by
proteins that regulate RNA binding proteins. These in-
clude the structural proteins at the heart of the spliceo-
some, such as SF3B complex or formin binding protein
21 (FBP21) (Bedford et al., 1998). It is possible to switch
splicing by designing synthetic, or discovering naturally
occurring, compounds that can interfere with this process.
One example is the discovery of borrelidin, an antifungal
compound,modifications ofwhich have been found to have
antiangiogenic activity in tumors and which bind to the
splicing protein FBP21(Woolard et al., 2011). The borre-
lidin analog BC194 appears to be able to coordinate
splicing of the vascular endothelial growth factor (VEGF)
gene to skip the normal 39 splice site used in tumor cells to
use an alternate downstream 39 splice site, resulting in a
protein with an alternate C terminus and that prevents
angiogenesis in vitro and in vivo. As the mechanism
through which FBP21 binds to the splice factors that
control VEGF are unknown, it may also affect splicing of a
number of other genes that control angiogenesis, but its
ability to bind FBP21 places it firmly in the category of
splicing inhibitors (Woolard et al., 2011).
A second example is the use of compounds that inhibit
splicing factor regulators, such as the splicing factor
kinase family. These kinases are a small family of proteins
that phosphorylate splicing factors of the SRSF1 family
and include SRPK1, SRPK2, CLK1-4, DYRK1-2, PIM1-2,
and PRP4. Inhibition of phosphorylation of the splicing
factor SRSF1, for example, resulting in altered splicing
of the downstream targetsMKNK2, hnRNPA2/B1, and
VEGF, all of which result in splice forms that switch
from protumorigenic [MKNK2b contributes to the ras-
mitogen-activated to mitogen activated protein kinases
(MAPK) pathway by phosphorylation of elongation
initiation factor 4E, which is oncogenic (Maimon et al.,
2014)]. VEGF-A165a is proangiogenic, and hnRNPA2 can
regulate VEGF-A translation to prevent translational
read-through and prevent expression of VEGFAx, an
antiangiogenic isoform (Eswarappa et al., 2014). SRSF1
has been shown to be a potent protumor splicing factor
(Karni et al., 2007). Studies overexpressing SRSF1 have
identified over 300 alternative splice variants that can be
regulated, many of which are thought to contribute to
tumor growth (see below) (Anczukow et al., 2015). Inter-
estingly, SRPK1 is overexpressed in many tumors (Fig. 2),
in contrast to other splice factor kinases such as CLK1,
which are downregulated. Moreover, SRPK1 has been
shown to be akey regulator ofmelanoma (Gammons et al.,
2014), acute myeloid leukemia (Siqueira et al., 2015);
glioma (Wu et al., 2013); hepatocellular carcinoma (Zhou
et al., 2013); and lung (Gout et al., 2012), breast, prostate
(Mavrou et al., 2015), pancreatic (Hayes et al., 2006),
colorectal (Hayes et al., 2007; Amin et al., 2011); and
ovarian cancer (Odunsi et al., 2012). In fact SRPK1
expression is a predictive biomarker for all-cause mortal-
ity in breast cancer (Li et al., 2014) and, given the effect of
upregulation of SRSF1 in this cancer type, it is perhaps
not surprising that SRPK1 targeting is a potential novel
therapeutic for cancer treatments.
V. Pathways Regulated by Alternative Splicing
The number of physiologic and pathologic processes
that appear to be regulated by alternative splicing is
increasing rapidly, and it is likely that alternative
splicing can contribute to all of the different cell process-
es. However, some processes have been at the forefront of
research into modulation of alternative splicing, and it is
these where the most advanced therapeutic approaches
have been developed. Although we focus here on apopto-
sis, angiogenesis, cancer, pain, and neuromuscular de-
generation, it is likely that modifications in splicing in
cognitive dysfunction (Scheckel et al., 2016), liver (Sehgal
et al., 2013) and lung disease (Nance et al., 2014),
inflammation (Hirata et al., 2015), and reproduction
(Ahmad andAhmed, 2004; Bills et al., 2009), amongmany
other processes, will come to the fore over the next few
years. However, we have focused on the more advanced
examples to provide proof of principle for how the new
pharmacology of splicing is being developed.
A. Apoptosis
Apoptosis, or programmed cell death, is an essential
mechanism in cell physiology, which often is deregulated
in disease. The molecules involved in both intrinsic and
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extrinsic apoptotic pathways have a large number of
splice variants reported. Interestingly, in many cases
these splice variants have antagonistic properties—i.e.,
pro- and antiapoptotic, which suggest that modulation of
ASmay be a quick and economicway for the cell to switch
its apoptotic potential depending on the intra- and
extracellular signals. A few examples are presented here.
Both caspase 8 and 9 have functionally different
isoforms. Whereas caspase 8 is normally proapoptotic,
an intron retention forms Cas8L with antiapoptotic
properties (Himeji et al., 2002). Skipping of exons 3, 4, 5,
and 6 in caspase 9 results in a shorter protein that also
has antiapoptotic properties—this event being regu-
lated by SRSF1 and SRSF2 (Shultz et al., 2010; Pan
et al., 2011). Yet another type of AS—59 alternative
splice sites—is responsible for a proapoptotic isoform of
the well-known survival factor Bcl-xL, termed Bcl-xS
(Cloutier et al., 2008). The balance between these two
isoforms is known to be regulated by SFs hnRNPA1 and
H/F as well as signaling through PKC (Shultz et al.,
2012). Alternate inclusion of exon 6 in the Fas receptor
results in either the trans-membrane protein, which is
proapoptotic, or a soluble receptor form with opposing
functions (Bonnal et al., 2008).
A theme that is emerging in several other physiologic
and pathologic processes, occurs in apoptosis too, co-
ordinated regulation of several splice isoforms to define
a specific cell function. Such is the example of the E2F1
transcription factor and the splice factor SRSF2 that
coregulate splice isoforms of several apoptosis genes,
c-flip, caspase 8, caspase 9, and Bcl-x (Merdzhanova
et al., 2008).
B. Angiogenesis
VEGFs, particularly the isoform VEGF-A165a, are the
principal angiogenic molecules in cancers and meta-
static lesions(Hurwitz et al., 2004), blood vessel growth
into the retina in blindness, and development of neo-
vasculature in neointimal hyperplasia in heart disease,
revascularization in peripheral and coronary vascular
disease, and progression of arthritis, psoriasis, and
many other diseases. The bioactivity of theVEGF ligands
and receptors is regulated by alternative RNA splicing
(Houck et al., 1992). VEGF-A is generated from a single
Fig. 2. Expression data from the GENT database of SRPK1 (A) and CLK1 (B) in different cancer types (relative to a normalized target density of 500,
using Affymetric microarrays) (Shin et al., 2011).
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gene by alternative splicing of eight exons (Harper and
Bates, 2008). Exons 5, 6, and 7 are alternatively spliced
to form isoforms of different lengths, with different hep-
arin binding properties, with the 189 amino acid isoform
beingmost heparin binding and the 110 or 121 amino acid
isoforms having least heparin binding (Ferrara et al.,
1991). Half of the isoforms, termed VEGF-Axxxa, where
xxx refers to the number of amino acids, are generated
using a proximal splice site in exon 8, resulting in a short
open reading frame (6 amino acids) and a stop codon. The
other half, the VEGF-Axxxb isoforms, use a distal splice
site in exon 8, resulting in the same size open reading
frame, and an alternate C terminus, which confers
antiangiogenic properties (Bates et al., 2002). The most
common of this family of splice variants (VEGF-A165b) is
endogenously expressed in normal tissues and down-
regulated in colon (Varey et al., 2008), renal, and
prostate cancer (Bates et al., 2002) and metastatic
melanoma (Pritchard-Jones et al., 2007). Interestingly,
anti-VEGF treatment, such as use of the antibody
bevacizumab, acts on both isoforms. In a post hoc study
in one of the registration trials of bevacizumab (ECOG
E3200), relative VEGF-A165b expression predicted effi-
cacy of bevacizumab treatment (Bates et al., 2012).
There have therefore been clear demonstrations that
VEGF splicing is critical not only for cancer growth but
also to resistance to anti-VEGF treatment.
Mechanisms controlling splicing of exon 8 are begin-
ning to be elucidated in model systems. SR proteins
such as SRSF1, SRSF2, and SRSF6 regulate VEGF-A
splicing; SRSF6 overexpression switches expression to
VEGF-A165b and SRSF1 to VEGF-A165a in epithelial
cells (Nowak et al., 2008) and in prostate (Mavrou et al.,
2015), melanoma (Gammons et al., 2014), and colorectal
(Amin et al., 2011) cancer cell lines. SRSF2 also regulates
VEGF-A165b splicing in lung cancer cells (Merdzhanova
et al., 2010). SRSF1 binding requires the 35 base region
in intron 7 immediately upstream of the proximal splice
site (VEGF-A165) (Nowak et al., 2010), whereas SRSF6
binding requires the 35 base region surrounding the
distal splice site (Nowak et al., 2008). Inhibition of
SRSF1 nuclear localization by blocking the SR protein
kinase SRPK1 inhibits VEGF-A proximal splice site
choice in exon 8 (Nowak et al., 2010) in all five cancer
cell lines (two uveal and one cutaneous melanoma, PC3
prostate, and LS174t colorectal) and two epithelial cell
lines (podocyte and retinal pigmented epithelial cells)
so far investigated. However, regulation of VEGF splicing
in cancer cells is still not well understood. We do not
know whether SRPK1 is ubiquitously required for
VEGF-A165 splicing, what controls SRPK1 activity, what
other components of the splice machinery are required,
andwhether SRPK1 inhibition is necessary or sufficient for
VEGF-mediated angiogenesis or other cancer processes.
It has also been shown that other splice factors can
control VEGF expression. In lung cancers, SRSF2 has
been implicated in controlling VEGF-A165b expression
(Merdzhanova et al., 2010), and in both podocytes
(epithelial cells of the renal glomerulus), retinal pig-
mented epithelial cells (Nowak et al., 2008), and
keratinocytes (Manetti et al., 2011), VEGF-A165b ex-
pression is switched on by TGFb1-mediated activation
of SRSF6. This results in overexpression of VEGF-A165b
in conditions such as systemic sclerosis, where TGFb1 is
overexpressed, and inhibition of angiogenesis, resulting
in ischemia and pain (Manetti et al., 2013).
VEGF-A acts through 2 cognate receptors, VEGFR1
and VEGFR2. Both of these are single transmembrane
domain receptor tyrosine kinases, which can be gener-
ated by alternative splicing to form either a full-length
functional protein that can bind its ligand, dimerize
(hetero and homo) and signal or can form alternate splice
variants that are truncated before the membrane span-
ning region by intron retention of intron 13 for VEGFR1
(Kendall and Thomas, 1993) or intron 10 for VEGFR2
(Vorlova et al., 2011). These splice variants result in a
soluble, secreted form of the protein that acts as an
antagonist to the ligands, binding them competitively
with the full-length receptor and preventing angiogene-
sis. The control of VEGFR2 splicing is unknown, and
VEGFR1 alternative splicing is still poorly understood,
despite the solubleVEGFR1 isoformbeing pathologically
upregulated in pre-eclampsia (Maynard et al., 2003), a
disease that is characterized by a syndrome of increased
blood pressure, reduced angiogenesis, and increased
vascular permeability.Mechanisms to regulate VEGFR1
splicing have not yet been translated into therapeutics
but there is potential to do so.
C. Cancer
Alternative splicing in cancer has been identified as a
key contributor to the diversity of gene expression and a
potential driver of nongenetic clonal expansion and
epigenetic diversity (Oltean and Bates, 2014). It also
suggests that resistance to treatment may be under-
pinned by alternative splicing and that the response of
the tumor to therapy may depend on alternative
splicing interactions (Abou Faycal et al., 2016). The
first indication that alternative splicing was a key
regulator of tumor growth was the discovery of the
oncogenic nature of SRSF1 overexpression. In 2007,
Adrian Krainer’s laboratory (Karni et al., 2007) at Cold
Spring Harbor, demonstrated that SRSF1 underwent
gene duplication inmany tumors and that relatively low
levels of overexpression were sufficient to transform rat
fibroblasts into sarcomas. They originally showed that
SRSF1 could exert these actions through three specific
RNA splicing events (switching MKNK2, Bin1 and
ribosomal S6 kinase 1, S6K1) but have recently identi-
fied, using an unbiased RNASeq approach, over 300 dif-
ferent alternatively spliced events resulting from
SRSF1 overexpression in breast cancer cell lines, of which
108 were also picked up by public database approaches,
and they investigated an additional five in cells in culture
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to show activity (Anczukow et al., 2015). The variety of
cellular activity stimulated by SRSF1 includes angiogen-
esis (Amin et al., 2011), apoptosis (Wang et al., 2014), loss
of tumor suppressor activity (Fregoso et al., 2013), trans-
lational control, and further splicing control defects (Amin
et al., 2011). Interestingly they did not see activity when
other SR proteins were overexpressed and, in fact, saw
repression when overexpressing SRSF2 and SRSF6.
These results, taken together with what is known of the
effect of VEGF splicing, indicate that coordination of
alternative splicing in cancer can lead to a procancer
phenotype or an anticancer phenotype, depending on the
activation of the different SR proteins.
Recent discoveries shed light on how primary onco-
genic proteins can regulate genome-wide alternative
splicing events in cancer. DNA damage appears to result
in arrest of theRNApolymerase at lesions induced by, for
instance, ultraviolet irradiation (Tresini et al., 2015).
This results in displacement of a subset of splicing factors
from the RNA polymerase and formation of RNA/DNA
hybrids between the pre-mRNA and the uncoiled DNA
known as R-loops (Aguilera and Garcia-Muse, 2012).
This appears to be able to activate ataxia telangiectasia
mutated kinase, which is now thought to be a key kinase
involved in stimulating a positive feedback loop resulting
in extended spliceosomemobilization, as well as a known
oncogene involved in modulating DNA repair processes.
Another key cancer driver, the oncogene Myc, was
recently shown to drive widespread changes in splicing,
including intron retention and weak 59 donor sites, and
that it can do so through interaction with specific
mechanisms such as arginine methyltransferases (e.g.,
prmt5) (Koh et al., 2015) and BUD31 (Hsu et al., 2015),
which have global effects on oncogenesis, proliferation,
and apoptosis. These recent findings lend weight to the
principle that targeting splicing could be a key driver for
novel cancer therapeutics.
D. Pain
Mammalian pain pathways are highly complex. The
peripheral signals indicative of tissue damage or in-
fection are detected by peripheral neurons, and the
input from these is processed at multiple levels of the
central nervous system, from spinal cord to cortex. The
ultimate perception of pain is dependent on the extent
and character of this neuronal processing (Millan,
1999). As a result of this complexity, there are many
cellular molecules/processes that can affect neuronal
properties and therefore alter the information encoded
within the pathway.Many of thesemolecules are known
to be alternatively spliced and could therefore be
potential targets for control of information transfer in
the pain pathways. To date, however, very little is
known about the functional implications of expression
of these splice variants and much less is known about
the control of the splicing. Most information is available
on the functional implications of expression of different
splice variants of the voltage gated calcium channels,
particularly Cav2.2. An alternative splice variant of this
channel is enriched in primary afferent nociceptors; the
presence of this variant increases sensitivity to neuro-
nal inhibition through opioid and GABA receptors (Bell
et al., 2004; Andrade et al., 2010). Pharmacological
inhibitors of this channel are in clinical usage, albeit
administered intrathecally because of blood-brain bar-
rier penetration problems, so consideration of the splice
variant expression and distribution is vital if similar
drugs are to be developed (McGivern, 2007). Splicing
control in pain pathways is therefore an area ripe for
investigation and for the development of interventions
for control of pain. We recently considered the potential
implications of splicing of multiple receptors/channels
important in pain pathways (Donaldson and Beazley-
Long, 2016), but given the early stage of this area, here
we concentrate on a review of the pharmacological
control of growth factor splicing in pain.
E. Growth Factors
Despite the importance of nerve growth factor (NGF)
in inflammation and nociception and the existence of
known splice variants, there is nothing reported on
whether NGF splice variants have different physiologic
actions. The splice variants of the high-affinity NGF
receptor TrkA do not differ functionally. Brain-derived
growth factor has multiple splice variants that, un-
usually, all produce the same peptide. It is thought that
inclusion of specific exons in the 59-untranslated region
of RNA controls the expression of specific mRNA
variants in specific tissues/conditions (Zheng et al.,
2012). VEGF and VEGF receptors have only recently
been implicated in nociception; inhibition of VEGF
actions at VEGFR2 can result in pain (Verheyen et al.,
2012;Hulse et al., 2014) and neuropathy (Verheyen et al.,
2012) through a reduction of neuroprotective actions of
VEGF (Verheyen et al., 2012, Beazley-Long et al., 2013).
More recent evidence also shows that alternative splicing
can generate algesic and analgesic VEGF isoforms,
suggesting that modulation of pain by VEGF may not
be solely due to actions on neuronal integrity but a direct
effect of different VEGF splice variants on peripheral
nociceptive neurons (Hulse et al., 2014). This is supported
by the observation that alternatively spliced VEGF iso-
forms can be neuroprotective against neuropathy and
analgesic (Hulse et al., 2015).
F. Muscle Function
Two diseases in which splicing defects have long been
identified to play a key role are spinal muscular atrophy
(SMA) and Duchenne’s Muscular Dystrophy (DMD). In
spinal muscular atrophy there is a loss of the SMN1
gene. The homolog SMN2 can replace many of the
functions of SMN1, but under normal conditions exon
7 is skipped, resulting in a premature stop codon and
nonfunctional protein. Repression of exon skipping can
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result in a functional SMN2 protein, which can sub-
stitute for the inactive genetically deficient SMN1 gene
that results in SMA (Miyaso et al., 2003). In DMD,
mutations in the 3685-amino acid-long coding region
that result in premature termination or nonfunctional
protein, either due tomis-splicing or due to introduction
of premature stop codons, result in disruption to the link
between the cytoskeleton and the cell membrane. The
C-terminal part of the protein is critical to its function,
but the multiple rod domains in the middle of this
exceptionally long protein can be missed out often with
little impairment of function. Therefore a mutation in
the middle of the gene that results in premature termina-
tion can often be overcomeby skipping the exon containing
the mutation, resulting in production of a slightly shorter
protein that is nevertheless functional.
Several SFs have been implicated in the regulation of
myogenesis and muscle function. Rbfox2 has been
shown to coordinate a network of AS events that define
myoblast differentiation and mature muscle formation.
In particular, two of the Rbfox2 targets, Mef2d and
Rock2, have been shown to be essential, because ex-
pression of their muscle-specific isoforms in RbFox2
depletedmyoblasts rescues the impaired differentiation
phenotype (Singh et al., 2014). RbFox1 is important in
regulating AS in skeletal muscle but also in cardiac
hypertrophy and heart failure (Pedrotti et al., 2015; Guo
et al., 2012). RBM20 is a key regulator of AS in cardiac
muscle and it is mutated in cardiomyopathies (Guo
et al., 2012). RBM24 is an RNA-binding protein also
shown to be essential in coordinating AS both in cardiac
and skeletal muscle; knockout of RBM24 in mice
revealed defects in heart development and sarcomero-
genesis (Yang et al., 2014). MBNL and cytidine-uridine-
guanidine binding protein and Elav-like family (CELF)
proteins are essential in coordinating AS in heart
development (Kalsotra et al., 2008) but have also been
shown to be involved in myotonic dystrophy. MBNL-1
is bound by the specific expanded repeats in the 39
untranslated region of the DMPK gene (Ho et al., 2004;
Orengo et al., 2008), and its reduced availability results
in defects of AS patterns and contribution to myotonic
dystrophy pathogenesis.
VI. Modulators of Alternative Splicing
A. Oligonucleotides
The generation of nucleotides that canmodify splicing
events is now proceeding apace, from in vitro models,
to in vivo models, and now into clinical trials. One
approach was to take a series of SRSF1 consensus se-
quences followed by a sequence complementary to a
specific splice site. In this case, transfection of cells with
this targeted oligonucleotide enhancer of splicing results
in stimulation of alternative splicing to a specific exon.
This has been demonstrated in vitro in cell free systems
and in intact cells, resulting in the extra inclusion of exon
7 in the SMN2 gene (Smith et al., 2014). The equivalent
has also been undertaken with antisense oligonucleo-
tides directed against SMN2 that contains the sequence
for the ISS in exon 7, which then sequesters the splicing
machinery that causes exon skipping, resulting in exon
inclusion and rescue of the disease phenotype (Hua et al.,
2007). This has now reached phase II clinical trial for
SMA. The challenge with this approach is to develop
compounds that can be given systemically, and that can
target the appropriate cell type.
There have therefore been numerous attempts to
develop therapeutic approaches for DMD using of anti-
sense oligonucleotides, which appear to be the most
advanced. Over 70% of DMD patients have mutations
between exons 45 and 55 contain, so targeting this
hotspot by inducing exon skipping has been a common
approach. Either single exon skipping (Spitali et al.,
2009; Yokota et al., 2012) or multiple exon skipping
(Aartsma-Rus and van Ommen, 2009) approaches have
been used using antisense sequences complementary
to exon splicing enhancers. Initial phase II data on the
systemic use of phosphorodiamidate morpholino olig-
omers, such as etiplirsen (NCT01396239) or drisa-
persen (NCT01153932), showed significant benefit in
small cohorts of children with the disease, with the
treatment preventing the decline in walking distance
over a six-month trial (Mendell et al., 2013; Voit et al.,
2014). These exon 51-skipping morpholino oligomers
recently entered phase III (NCT02255552, NCT01480245)
clinical trials, although drisapersen recently received a
setback when the Food and Drug Administration con-
cluded that the standard of substantial evidence of effec-
tiveness had not been met.
B. RNA Binding Inhibitors/Activators
The outcome of AS events may be modulated by
small molecules that bind directly to RNA, either at
splice sites or at regulatory sequences (ESEs, ESSs,
ISEs, ISSs). They may interfere directly with the
tertiary RNA structure or hamper protein-RNA in-
teractions. They may inhibit or activate the usage of a
certain splice site. One approach has been to screen
compounds for their ability to affect splicing using
minigenes that express specific splice isoforms, then
only selecting compounds that have specificity for
that splice event (Naryshkin et al., 2014). This pro-
cess has been shown to successfully identify com-
pounds that are speculated to bind specifically to the
RNA of the SMN2 gene and promote inclusion of exon
7 (Naryshkin et al., 2014). The exact nature of the
interaction of this compound is not yet known, but it
has been speculated that it binds either to the RNA
itself or to the RNA binding domain of the splicing
factors required for SMN2 exon 7 skipping (Palacino
et al., 2015). One of these compounds (NVS-SM1, now
known as LMI070) has now reached clinical trial
(NCT02268552).
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C. Splicing Factor Kinase Inhibitors
The activity of SR proteins is regulated by phosphor-
ylation of their RS domain. Phosphorylation promotes
the spliceosome assembly by facilitating protein-protein
interaction; moreover it prevents the SR proteins from
binding randomly on the RNA. Phosphorylation also
has a role in the SR proteins’ localization and distribu-
tion in the nucleus and in the organization of the
speckles, which are subnuclear structures where the
SR proteins are concentrated. The phosphorylation of
these proteins must be tightly regulated, because both
hyper- and hypophosphorylation have been shown to
reduce their overall activity (Prasad et al., 1999). Once
the spliceosome is formed, dephosphorylation of the
SR proteins is necessary for the transesterification cut-
and-paste reaction to take place. Therefore, a cycle of
phosphorylation-dephosphorylation is essential for the
splicing to occur, marking the transition between stages
in each round of the splicing reaction (Hagiwara, 2005;
Plocinik et al., 2011). The SR protein phosphorylation
levels are controlled by three main families of splicing
kinases: CDC2-like kinases (CLKs), dual-specificity
tyrosine-regulated kinases (DYRKs), and SR-rich splic-
ing factor protein kinases (SRPKs). The PIM1, PIM2,
and PRP4 kinases are also known to play roles in the
control of phosphorylation of splicing factor proteins.
1. CDC2-like Kinases. The CDC2-like kinases
(CLKs) are an evolutionarily conserved group of dual-
specificity kinases, capable of phosphorylating protein
substrates on serine, threonine, and tyrosine residues.
They specifically interact with RNA binding proteins,
especially the members of the SR family of splicing
factors (Prasad et al., 1999). CLKs contain a C-terminal
domain, which is highly conserved in all the members of
the family, and an N-terminal domain, which is non-
catalytic and enriched with RS dipeptide residues. This
region is important for interaction with SR proteins, and
the main differences between family members can be
found in this domain (Hanes et al., 1994; Nayler et al.,
1997). The family consists of four isoforms (CLK1–4).
CLK1 (which is also known as Clk/Sty) efficiently
phosphorylates SR protein SRSF1 on its RS domain,
affecting its ability to bind RNA and other proteins
(Colwill et al., 1996; Xiao and Manley, 1997). Catalyt-
ically inactive forms of CLK1 colocalize with SR pro-
teins in the nuclear speckles, whereas the active form
phosphorylates SR proteins, which causes speckles to
dissolve and leads to the redistribution of SR proteins in
the nucleus (Colwill et al., 1996). CLK1 also autophos-
phorylates on both serine/threonine and threonine
residues, which influences the pattern of phosphoryla-
tion on SRSF1 and the ability of CLK1 to recognize
different SR proteins (Prasad et al., 1999). Differential
phosphorylation of SR proteins by the CLK kinasesmay
be one of the mechanisms that characterize the late
phase of virus replication. In fact, CLKshave been shown
to play a role in the control of the alternative splicing of
adenovirus E1A pre-mRNA in vivo (Duncan et al., 1998).
CLKs have also been associated with the alternative
splicing of important proteins such as tissue factor (TF)
and tau. TF is an essential cofactor for the activation of
blood coagulation in vivo, and elevated intravascular
levels of TF have been reported in a variety of prothrom-
botic diseases. The pre-mRNA splicing of TF is controlled
by CLK1 and is associated with increased TF protein
expression, procoagulant activity, and accelerated clot
formation. Interruption of CLK1 signaling prevents TF
from accumulating in activated platelets (Schwertz et al.,
2006). The CLKs also regulate the alternative splicing of
microtubule-associated protein tau. Mutations of this
protein due to aberrant splicing are implicated in fronto-
temporal dementia and Parkinson’s disease (Hartmann
et al., 2001).
One of the first reported inhibitors of the CLK family
was 5,6-dichloro-1-b-D-ribo-furanosylbenzimidazole (Fig.
3A; Nayler et al., 1998). However, this compound is also
a potent inhibitor of casein kinase 2 and positive
transcription elongation factor in a competitive fashion,
which limits its utility (Marshall et al., 1996). Hagiwara
and colleagues (Muraki et al., 2004) reportedTG003 (Fig.
3B) as a small molecule with low-nanomolar IC50 values
for CLK1 and CLK4. Thismolecule was identified from a
high-throughput chemical screen of over 100,000 com-
pounds and has proved to be a useful tool molecule.
Further work by Mott et al. (2009) demonstrated that
TG003 binds to CLK1 (19 nM), CLK2 (95 nM), CLK4
(30 nM), and DYRK1A (12 nM), as well as having cross
reactivity with casein kinase (CK1d and CK1«), dual-
specificity tyrosine phosphorylation-regulated kinase
(DYRK1B), yeast Sps1/Ste20-related kinase (YSK4),
and proviral insertion site in Moloney murine leukemia
virus (PIM) kinase isoforms.
Thomas and coworkers (Mott et al., 2009) prepared a
series of substituted 6-arylquinazolin-4-amines that were
found to be potent inhibitors of the CLKs. Like TG003, it
was found that these compounds also were potent
DYRK1A inhibitors. The best hit (Fig. 3C) presented
nanomolar activity against CLK1 (30 nM), CLK4 (50 nM),
and DYRK1A (27 nM) and showed excellent selectivity
when tested on a panel of 402 kinases, especially in
comparison with TG003 (Mott et al., 2009; Ghosh and
Adams, 2011; Coombs et al., 2013; Morooka et al., 2015).
Expansion of this work was reported in 2011, with the
development of 6-arylquinazolin-4-amines that have im-
pressive potency and selectivity. Selected inhibitors pos-
sess activity versus CLK1, CLK4, and DYRK1A below
100 nM (Rosenthal et al., 2011).
Further work by Thomas, in collaboration with Aubé,
has led to the report of a chemical probe ML315 (Fig. 3D),
which is an aryl-substituted aminopyrimidinewith activity
against the CLK and DYRK families of kinases (Coombs
et al., 2013). Its off-target pharmacology and in vitro
pharmacokinetic properties have been further evaluated
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and, given that it is a selective CLK/DYRK inhibitor with
adequate solubility, stability, and cell permeability, it is
recognized as being suitable for cell-based biologic studies
(Coombs et al., 2013).
In 2011, Knapp and coworkers (Fedorov et al., 2011)
reported two new CLK1 nanomolar inhibitors, KH-
CB19 (Fig. 3E, as E isomer) and KH-CB20 (Fig. 3F, as
E/Z mixture), which are analogs of the marine natural
product bauerine C. Both were potent CLK1 inhibitors
(20 nM, 16 nM, respectively) but also had some potency
against DYRK1A (55 nM, 58 nM, respectively). X-ray
cocrystal structures with both CLK1 and CLK3 revealed
that KHCB19 has a unique noncanonical binding mode,
which helps to rationalize its selectivity.
Studies into the marine sponge natural product leu-
cettamine B (Fig. 3G) have led to the report of a new
family of inhibitors, known as leucettines, with one of
them, leucettine L41 (Fig. 3H) found to inhibit CLK1
(15 nM), DYRK1A (40 nM), andDYRK2 (35 nm) (Debdab
et al., 2011).
Leucettine L41 (Fig. 3H) was cocrystallized with
CLK3, which confirmed that these compounds are
ATP-competitive inhibitors. Importantly, G was found
to inhibit the phosphorylation of SR proteins SRSF6
and SRSF4 in vitro and in vivo andwas demonstrated to
modulate alternative pre-mRNA splicing of Clk-1 in a
cell-based reporting system (Debdab et al., 2011). The
submicromolar cellular activity of these compounds
makes them valuable as chemical probes.
2. Dual-specificity Tyrosine-Phosphorylation-Regulated
Kinases. The dual-specificity tyrosine-regulated kinases
(DYRK) family consists of five mammalian subtypes
including 1A, 1B, 2, 3, and 4. This family phosphorylates
proteins on serine, threonine, and tyrosine residues and is
highly conserved across species, It shows very little
homology with other kinases outside the catalytic domain
(Smith et al., 2012).
DYRK1A has been shown to accumulate in nuclear
speckles and is known to phosphorylate a multitude of
proteins involved in a wide variety of signaling path-
ways in vitro (Alvarez et al., 2003). In particular,
DYRK1A phosphorylates the SR proteins and SF3b1,
a subunit of the U2 snRNP-associated complex SF3b,
the only non-SR component of the spliceosome known
to be phosphorylated during splicing catalysis (Tejedor
and Hämmerle, 2011; Wang et al., 1998). However, the
specificity of DYRK1A in vivo is poorly defined (Tejedor
and Hämmerle, 2011). Although the exact cellular
functions of this kinase are still unknown, it is thought
to play a critical role in the development of Down syn-
drome and Alzheimer’s disease. In fact, the DYRK1A
gene is located within the Down syndrome critical region
of chromosome 21, and increased activity of DYRK1A has
been reported in various brain compartments in subjects
that suffer from Down syndrome and other neurodegen-
erative diseases, including Alzheimer’s, Parkinson’s,
Huntington’s, andPick’s diseases (Tejedor andHämmerle,
2011; Smith et al., 2012).
Fig. 3. Structures of splicing factor kinase inhibitors. (A) 5,6-dichloro-1-b-D-ribo-furanosylbenzimidazole (CLK inhibitor). (B) TG003 (CLK inhibitor).
(C) 6-arylquinazolin-4-amine CLK/DYRK inhibitor. (D) ML315 CLK/DYRK inhibitor. (E) KH-CB19 and (F) KH-CB20, both baurine analogs. (G)
Leucettamine B. (H) Leucettine L41. (I) harmine. (J) EPCGg, (K) INDY (L) ID-8, (M and N) 10-iodo-11H-indolo[3,2-c]quinoline-6-carboxylic acids—all
DYRK inhibitors. (O) SRPIN340 SRPK inhibitor. (P) SPHINX, SRPK1 inhibitor. (Q) Compound A-PRP4 inhibitor.
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One of the first inhibitors of DYRK1A to be discovered
was harmine (I, Fig. 3). It is a b-carboline alkaloid, first
isolated from a South American vine, and has been
shown to inhibit DYRK1A in vitro with an IC50 of 80 nM
(Bain et al., 2007).However, its selectivity is poor, because
it is a potent inhibitor of other important enzymes such as
monoamine oxidase and cyclin-dependent kinases. More-
over it possesses significant drawbacks, such as halluci-
nogenic properties, due to its affinity for serotonin and
tryptamine receptor binding sites. Another potent in-
hibitor of DYRK1A is epigallocatechin gallate (J, Fig. 3),
a natural polyphenol component of green tea, with an IC50
of 330 nM (Bain et al., 2003). Although polyphenols are
known to have a rather nonselective activity against a
variety of enzymes and transcription factors, epigalloca-
techin gallate shows selective inhibition of DYRK1A and
it is considered safe for human consumption, although it is
not very potent.
INDY (Fig. 3K) was also developed by the Hagiwara
laboratories (Ogawa et al., 2010). Although it is closely
related to TG003, it has a different kinase inhibition
profile. It inhibits both DYRK1A (240 nM) andDYRK1B
(230 nM), while also having significant activity against
DYRK2 (97% inhibition at 10 mM), CLK1 (99% at
10 mM), and CLK4 (100% at 10 mM).
ID-8 (L, Fig. 3) is an indole derivative identified by
Miyabayashi et al. (2008) (as part of an investigation
focused on identifying small molecules that can self-
renew embryonic stem cells). Using affinity chromatog-
raphy, it was found that ID-8’s molecular target was the
DYRKs, although no kinase inhibition assays were
carried out (Hasegawa et al., 2012).
Asmentioned,many inhibitors that are active against
CLKs also show potent activity on DYRK kinases, such
as the 6-arylquinazolin-4-amines (C, DYRK1A 12 nM,
DYRK1B 25 nM) (Rosenthal et al., 2011; Mott et al.,
2009), ML315 (D, DYRK1A 282 nM) (Coombs et al.,
2013), TG003 (B DYRK1A 930 nM) (Muraki et al.,
2004), INDY (K DYRK1A 240 nM, DYRK1B 230 nM)
(Ogawa et al., 2010), and leucettine L41 (H, DYRK1A
60 nM, DYRK1B 44 nM, DYRK2 73 nM) (Debdab et al.,
2011).
Although CLKs and DYRKs are both members of the
CMGC branch of the kinome that include cyclin-
dependent kinases, mitogen-activated protein kinases,
glycogen synthase kinase, and casein kinase 2, there is
only 32.8% homology between DYRK1A and CLK1A,
which would suggest that dual inhibition of these
kinases should be challenging. However, closer exami-
nation of the ATP binding domain reveals that there are
several conserved amino acids residues, making the
ATP binding site very similar and explaining the dual
inhibition observed. Until 2015, it was felt that it may
not be possible to generate selective inhibitors that
target just one of these kinase families. However, in
2015, Kunick and coworkers (Falke et al., 2015) report-
ed two 10-iodo-11H-indolo[3,2-c]quinoline-6-carboxylic
acids (M and N), which are the first DYRK1A-selective
compounds. These two compounds have nanomolar
potency against DYRK1A (6 and 22 nM, respectively).
Moreover, they are selective not only versus the CLK
family (for CLK1, 500 and 2000 nM respectively) but also
versus the structurally and functionally related DYRK
isoforms [DYRK1B (600 and .10,000 nM) and DYRK2
(.10,000 and .10,000 nM, respectively)], proving that
it is possible to achieve selectivity between those ki-
nases. Although the physicochemical properties of these
compounds need to be optimized for cellular studies, the
identification of this scaffold represents a significant step
forward in the development of molecules that can selec-
tively control the DYRK kinases.
3. SR Protein-specific Kinases. SRPKs are a family
of serine/arginine protein kinases that specifically
phosphorylate serine in serine-arginine dipeptide resi-
dues (Papoutsopoulou et al., 1999). The human genome
includes over 100 proteins containing RS domains,
indicating that SRPKs could regulate many cellular
functions through the phosphorylation of these sub-
strates. A large portion of the RS domain-containing
proteins is represented by the SR splicing factors, and it
has been shown that these proteins are substrates for
SRPKs, indicating that these kinases play a central role
in the regulation of splicing. In fact, they provide a basal
level of phosphorylation that is thought to play a role in
the regulation of the intracellular localization of splic-
ing factors (Giannakouros et al., 2011). The SRPK family
contains three isoforms: SRPK1, SRPK2, and SRPK3.
The domain arrangement in this family of kinases is
unique; in fact they contain a large insert, called the
spacer domain, that bifurcates the kinase core. The space
domain plays a key role in the subcellular localization of
these kinases (Lukasiewicz et al., 2007).
The first kinase of this family to be fully characterized
was SRPK1. It consists of an amino-terminal glycine-
rich region, followed by a SH3 domain (a small protein
domain of about 60 amino acids residues) and a kinase
domain similar to both tyrosine and serine/threonine
kinases. Next to this, are two leucine/isoleucine zipper
motifs and a stretch of basic amino acids. The C terminus
is basic, with 24% of the residues being prolines (Gallo
et al., 1994). The two ends of the previously mentioned
space domain fold into unique helical structures and
interact with the kinase core (Lukasiewicz et al., 2007).
SPRK1 has been shown to specifically induce the
disassembly of nuclear speckles and is thought to have a
central role in the regulatory network for splicing,
controlling the intranuclear distribution of splicing
factors in cells during interphase and the reorganiza-
tion of nuclear speckles during mitosis (Colwill et al.,
1996). SPRK1 also plays a critical role in regulating the
function of vascular endothelial growth factor (VEGF),
which,whendysregulated, stimulates blood vessel growth
in cancer (Nowak et al., 2010) and induces cisplatin
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resistance in human ovarian carcinoma cell line (Wang
et al., 2015).
SPRK2 is highly homologous to SPRK1 with the key
difference being a proline-rich tract at the N terminus
and an acidic region in the spacer domain (Giannakouros
et al., 2011). SPRK2 specifically interacts with one of the
SR proteins, acinus, which is a proapoptotic arginine-
serine domain-containing protein. It has been shown
that overexpression of either acinus or SRPK2 increases
leukemia cell proliferation (Jang et al., 2008). Moreover
both SPRK1 and SPRK2 are responsible for hepatitis B
virus core protein phosphorylation during viral infection
(Daub et al., 2002). SRPK3 is expressed in the heart and
skeletal muscles and is required for normal muscle
growth and homeostasis (Giannakouros et al., 2011).
There have been a number of SRPK inhibitors de-
veloped, including tricyclic quinoxalones (Szekelyhidi
et al., 2005), with IC50 values ranging from 40 nM to
1 mM and some selectivity over other kinases (although
the most potent are also c-src inhibitors), the isonicoti-
namides [e.g., SRPIN340 (Fig. 3O) (Fukuhara et al.,
2006)] that have good selectivity and reasonable po-
tency (;1 mM), and the trifluoroanilino-disubstituted
furans [SPHINXes (Fig. 3P) (Gammons et al., 2013b)]
that are potent (,10 nM) and selective. SRPIN340 was
identified via high-throughput screening and found to
have low micromolar inhibition activity on SRPK1 (0.89
mM) and millimolar activity on SRPK2 (Fukuhara et al.,
2006). SRPIN340 is a isonicotinamide compound that
also features as key elements a phenyl ring functional-
ized with a trifluoromethyl group and a piperidine ring.
Recent work by Morooka et al. (2015) has led to the
cocrystallization of SRPIN340 with SRPK1 and revealed
a unique binding mode for this kinase, although the
compound is still an ATP-competitive inhibitor. The
kinase catalytic domain of SRPK family members is
characterized by a unique domain insert in the kinase
hinge region (Ghosh and Adams, 2011). Structures of
SRPK kinases revealed that a helix in this SRPK
insertion domain packs adjacent to the kinase hinge
region, creating a unique hydrophobic pocket located
between helix aG and aH. The CF3 group on N was
oriented toward this hydrophobic pocket in the unique
helical insert, and to accommodate this, the backbone
carbonyl of the hinge residue L168 flipped tomake room
for the trifluoromethyl group.
Bates, Knapp, and coworkers (Gammons et al.,
2013b) used an in vitro kinase assay, as well as temper-
ature shift assays, to identify the disubstituted furan
SPHINX (P, Fig. 3) as a selective inhibitor for SPRK1
(0.44 mM). The SPHINX structure shows similarity with
SRPIN340, retaining the trifluoroanilido moiety but
with structural variation in the other substituents. It
was found that SPHINX reduced expression of proangio-
genic but not antiangiogenic VEGF isoforms. Signifi-
cantly, it and SRPIN340 significantly reduced choroidal
neovascularization in vivo, and as such, these molecules
represent a major stepping stone for the treatment of
diseases such as aged macular degeneration.
4. Pre-mRNA Processing Factor Kinase 4.
Pre-mRNA processing factor (PRP) 4 is a kinase of the
DYRK family and is a serine-threonine kinase with an
N-terminal arginine/serine-rich domain, and it is
known for its role in regulating pre-mRNA splicing
(Schneider et al., 2010). It binds pre-mRNA splicing
factors SFRS8, PRP6, and pinin. It is an essential
kinase that associates with both the U5 snRNP and the
N-CoR deacetylase complexes. Gao et al. (2013) demon-
strated how the activity of kinase PRP4 is essential for
the regulation of cancer cell growth and survival, in-
dicating the potential interest of PRP4 as a therapeutic
target in oncology. The substrates for this enzyme are
numerous, including other kinases and transcription
factors. In this work they also reported the only inhibitor
of PRP4, compound A (Q), which showed nanomolar
inhibition on PRP4 (16 nM) but, unfortunately, its low
cellular permeability and poor solubility will limit its
application as a chemical probe.
5. Proviral insertion site of Moloney murine leukemia
virus kinases. Proviral insertion site of Moloney mu-
rine leukemia virus kinases (PIM-1, PIM-2, and PIM-3)
are constitutively active serine/threonine kinases that
are known to regulate cell survival (Morwick, 2010).
They are overexpressed in a number of human malig-
nancies and inflammatory states, and as such, there has
been much interest in developing inhibitors of these
kinases for the treatment of cancers and autoimmune
diseases (Burger et al., 2013). The role of the PIM
kinases in alternative splicing is not well understood,
with the phosphorylation target proteins for Pim-1 and
the mechanisms underlying these processes still being
elucidated. However, there has been some focus on
PAP-1, because this protein is implicated in autosomal
dominant retinitis pigmentosa, which is the most
common form of hereditary retinal degeneration. Ariga
and coworkers (Maita et al., 2000, 2004) have shown
that phosphorylation of PAP-1 is regulated through a
Pim-1-controlled signaling pathway and that the degree
of phosphorylation of PAP-1 is correlated with its
splicing activity. However, to date, no reports on the
use of a PIM-1 kinase inhibitor has been reported on
this pathway.
VII. Considerations for Drug Development
A. Screening Cascades
To develop compounds that are able to result in
altered splicing that results in improved outcome for
patients, it has become necessary to set up screening
cascades for therapeutic development that have some
unique components to them. One example is the devel-
opment of compounds that result in inhibition of
splicing factor kinases, but similar approaches could
be, and have been, applied to many approaches where
74 Bates et al.
splicing is the target. During normal drug development,
a hit to lead screening process is undertaken whereby
the molecular target is a key component; for instance,
developing an inhibitor of the VEGFR would require a
screen of a library against an in vitro kinase assay,
using a high-throughput screen. For alternative splic-
ing, the key point is whether the alternative splicing is
modulated, and the target may not be identified early.
So one way to screen is to undertake a high-throughput
screen using a readout of splicing. Successful examples
of this include using reporter genes, whereby two
different colors are generated according to the splice
site (Bonano et al., 2007). These minigenes have been
developed for a while against alternatively spliced
proteins such as SMN2 (Cherry et al., 2012) and
FGFRIII (Bonano et al., 2006). A high-throughput screen
can then be undertaken using cells as a marker to
identify compounds that can affect splicing of the specific
gene (Cherry et al., 2012). However, this approach is
likely to result in a large number of false positives,
because compounds that differentially affect transcrip-
tion could also alter splicing because of the processivity of
the spliceosome—increased (or decreased) transcription
rates can change the splice sites identified (Nogues et al.,
2003). Therefore usingmultiple reporters to identify that
the gene of interest is alternatively spliced and other
alternatively spliced genes are not altered is useful.
Second, the screening cascade needs to ensure that the
effect is specific, so testing the effect across a variety of
spliced products that are known to be within the target
tissue (i.e., within muscle, are there effects on other
known splice variants?) or within the known target
profile (i.e., for SRSF1 mediated targets, are all SRSF1
known genes altered or just a few?). This can also be done
across the whole transcriptome using RNA sequencing
followed by bioinformatic analysis that allows the
difference in mRNA expression between two isoforms
from the same gene to be examined in highly expressing
genes. This type of specificity screening, as shown by
Naryshkin et al. (2014), indicates that specificity for
splicing can be achieved. A series of toxicity analyses
needs to be carried out aswould be the case for any other
drug, but in this case it is worth considering that the
effects may not be on the potential targets themselves,
but on alternative splicing of the targets. For instance,
many studies need to investigate the action of the drug
on the human ether-a-go go-related gene product—a
potassium channel involved in repolarization of the
cardiac action potential. Standard screening cascades
would include a hERG activity screen using cells over-
expressing hERG from a cDNA. If the effect is not on the
channel itself but on alternative splicing of the channel
then endogenous hERG expressing cells need to be
investigated instead (Kupershmidt et al., 1998). This
also applies to numerous other toxicity and pharmaco-
kinetic studies, including CYP inhibition, metabolism,
and breakdown of the targets.
B. Biomarkers
For most drugs, the knowledge that the agent is
having the desired biologic effect is a critical part of the
development program. A biomarker of efficacy is key.
However, for alternative splicing modulators this can
pose a problem, because there may be multiple down-
stream pathways that are modified and these may be
cell type, tissue type, and context dependent. For in-
stance, targeting a component of the alternative splic-
ing pathway such as a SR protein may produce different
downstream alternative splicing (or none) in some
tissues and desirable consequences in the target tissue.
Thus biomarkers of efficacy need to be chosen carefully
and specifically for each target type. SR kinase inhibi-
tors can use the target phosphorylation as a biomarker of
efficacy, for instance by immunoprecipitation of the SR
protein followed by Western blotting for phosphoserine or
phosphoSR, but inhibitors of the spliceosome such as
spliceostatin have a more difficult biomarker problem,
because the effectwill be to disrupt splicing ofmany genes,
and the therapeutic window is therefore narrower. Using
oligo-targeted therapies gives a more subtle biomarker,
because it is possible that only a single RNA species may
be changed. It is difficult using standardquantitativeRNA
techniques to measure RNA changes in splicing quantita-
tively, because qPCR is designed to detect fold changes or
order of magnitude changes due to the logarithmic re-
lationship of PCR. A novel technology to determine
splicing changes that has been developed is digital droplet
PCR (Hindson et al., 2013), which is capable of quantifying
a few percent change (Sun et al., 2014), and has been used
to identify changes in RNA splice variants of androgen
receptor in a few circulating tumor cells in prostate cancer
(Ma et al., 2016). Alternatively RNA-seq can be used to
determine splicing changes by investigating splice junc-
tion reads (Anczukow et al., 2015). This is expensive but
can be highly sensitive.
C. Off Target Effects
As with any drug development, possible off-target
effects should be considered. Relatively recently there
has been a reluctance in the field that specificity in
splicing therapeutics may be ever achieved, knowing
the immense number of splice sites and the conserved
consensus sequence at these sites. However, clues that
this might be possible came from the elucidation of how
specificity of splice sites choice is accomplished through
a complex interaction of RNA tertiary structure and
SFs. Indeed, two recent screens from Roche and Novar-
tis of cells expressing splicing reporters (HEK cells or
NSC34motor neuron cell lines, respectively) using large
chemical libraries (Naryshkin et al., 2014; Palacino
et al., 2015) have revealed small molecules that are
incredibly specific for a certain splice site targeted in the
SMN gene. RNA-seq analysis has shown a very small
number of additional splice sites being affected.
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Targeting splicing regulators that are once or twice
removed from RNA (e.g., splicing factor kinases) is likely
to affect several splice sites and genes. However, alterna-
tive splicing is cell and tissue specific, and therefore it will
be important to define functionally whether modification
of additional splice sites than those intended is important
in the system to be studied. Indeed, we recently showed
that knockdown of SRPK1 in PC3 prostate cancer cells
predominantly affects their angiogenesis potential
through modifying VEGF splicing (Mavrou et al., 2015)
and not other properties (e.g., proliferation, migration),
whereas in breast cancer cell lines SRPK1 knockdown
induces apoptosis (Hayes et al., 2007), but the mecha-
nisms behind this specificity are not yet elucidated.
Off target effects could also be limited by designing
routes of administration of inhibitors—for instance
using topical delivery of compounds or by injection into
a restricted space such as the vitreous of the eye. This
approach has been used in preclinicalmodels for SRPK1
inhibitors in models of retinopathy of prematurity
(Gammons et al., 2013a) and choroidal neovasculariza-
tion (Gammons et al., 2013b).
D. Safety
The safety profile of modulators of alternative splicing
is regularly questioned during the development of modu-
lators of this process. The two different types of splicing
modulation—constitutive and alternative splicing—are
expected tohave substantially different safety and toxicity
profiles. Early results with modulators of constitutive
splicing indicated substantial toxicity, but recent studies
with the SF3B1 inhibitor spliceostatin and pladeolinide B
indicate that even targeting constitutive splicing may not
have toxicity levels greater than that associated with
modulators of other constitutive cellular processes, such
as the cell cycle inhibitors, cytoskeletal inhibitors or
channel blockers.
The safety profile of alternative splicing modulators
has not been clearly established and, of course, is likely to
be different for each pathway, but preliminary studies
appear to provide remarkably good safety profiles. Inhib-
itors of SRPK1 have been shown to be given systemically
at supratherapeutic doses in animals without any clear
side effects (Fukuhara et al., 2006), and nucleotide
specific inhibitors are considered to be highly specific
and therefore less prone to toxic side effects. The recent
suspension of the clinical trial involving alternative
splicing inhibitors of the SM2 gene due to potential off
target effects in animal models will be an interesting
development to follow, but even here, no clear indication
of toxicity was reported in patients at this time.
VIII. Conclusions and Future Directions
The development of splicing inhibitors as therapeutic
compounds is in its infancy, with the first targeted
splicing inhibitors only just reaching phase III clinical
trials. However, compounds that regulate splicing are
already used in clinical practice—valproate (Brichta
et al., 2006), amiloride (Chang et al., 2011), and caffeine
(Shi et al., 2008)—have all been shown to regulate
splicing (of SMN2, BClx, and KLF6, respectively)
through modulation of splicing factors. The new gener-
ation of specific highly targeted compounds is likely to
usher in a new era of splicing regulators, with multiple
mechanisms of action and targets.
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